Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Absci Corporation (ABSI) Stock Down 13.73% Today?

Why Is Absci Corporation (ABSI) Stock Down 13.73% Today?

Key Takeaways

  • Absci Corporation (ABSI) fell 13.73%, or $1.16, to $7.29 in Monday morning trading, down from Friday's close of $8.45.
  • The immediate catalyst was an analyst price-target trim: Guggenheim cut its target to $14 from $15 while keeping a Buy rating after rebuilding its model for third-quarter results.
  • Secondary driver: a deepening post-earnings de-rating that has now erased roughly 28% of the share price in three sessions, following a revenue miss on Nov. 12.
  • Positioning ahead of December's 13-week interim proof-of-concept data for lead asset ABS-201 in pattern hair loss is adding to volatility, with the readout now weeks away.
  • The stock has broken below its 50-day moving average near $9.65, though it remains far above its 200-day average near $6.83 and a 52-week low of $2.24.
  • Traders are watching whether $7 holds into the December interim readout, and whether the analyst consensus target near $13.70 continues to drift lower.
  • News Significance Score: 29/100 — A modest target trim drove a move about 2.6 times the stock's typical daily swing.
  • For deeper detail on Price Targets, Earnings, and Forecast, explore the dedicated Absci pages on Tickeron.
  • You can also review Trending AI Robots to see which automated strategies are performing best in the current market.

Opening Summary: Absci Extends Its Slide

Absci Corporation (ABSI) is a Vancouver, Washington-based clinical-stage biotech that uses generative AI and a high-throughput synthetic biology lab engine to design biologic drugs, and is now betting its future on ABS-201, an anti-prolactin receptor antibody in development for pattern hair loss and endometriosis. Shares dropped to $7.29 in the current session, a decline of 13.73% from the prior close of $8.45 — a loss of $1.16 per share. The direction is unambiguously lower. The verified catalyst is an analyst price-target reduction issued before the opening bell, layered on top of a broader post-earnings reset triggered by a third-quarter revenue shortfall reported on Nov. 12.

Analyst Price Target Cut Sets the Tone

Guggenheim lowered its 12-month target on ABSI to $14 from $15 on Monday while reiterating a Buy rating. The firm said it had updated its model following third-quarter results and a subsequent management conversation, with the cut largely reflecting technical adjustments — most notably a shift to a fully diluted share count in its discounted cash-flow work — rather than a change to the underlying investment thesis.

The note also flagged that the shares could be unusually volatile before and around the December data release. That characterization looks prescient: even at $7.29, the stock sits roughly 92% above the analyst target, which explains why a modest trim to the target has not triggered fresh downgrades but has nonetheless removed a psychological support level for momentum holders.

Post-Earnings De-Rating Still in Motion

Today's move is best understood as the third leg of a repricing that began with the third-quarter report. Partner program revenue came in at $0.3 million against expectations near $0.7 million, while net loss widened to $33.3 million, or $0.19 per share — a figure that was broadly in line, meaning the revenue line carried the disappointment. Research and development spending climbed to $23.6 million from $19.2 million a year earlier as ABS-201 costs ramped.

Cash, equivalents, and marketable securities stood at $173.7 million at quarter-end, with management guiding to a runway into the second half of 2028. That is a comfortable cushion for a company burning roughly $35 million a quarter, but it also points to the structural issue: with the stock near a $1.26 billion market cap and trailing revenue of about $1.5 million, valuation rests almost entirely on a single clinical readout. From the $10.12 close on Nov. 11 through today's $7.29, the shares have lost almost 28%.

Positioning Into the December Readout

Absci expects to report 13-week interim proof-of-concept data for ABS-201 in male pattern hair loss in December 2026, with full 26-week data in early 2027 and a Phase 2 endometriosis trial planned for mid-2027. Management has framed the interim cut as a directional signal of biological activity across target-area hair count, total hair count including vellus hairs, and hair width, with pooled safety data. Because the study remains blinded to 26 weeks, the interim dataset will be limited and cohort-skewed — a setup that invites de-risking by investors who would rather re-enter after the event than carry binary exposure through it.

Market Context and Trading Activity

Volume has been running above its three-month average of roughly 3.8 million shares during the selloff, with 5.5 million shares changing hands on Friday alone, suggesting distribution rather than a single thin-print dislocation. The move is company-specific in character but amplified by the stock's high beta of about 2.2 and by sector-wide caution toward unprofitable, AI-adjacent biotech names that had rallied hard this year — ABSI is still up more than 140% year to date.

Technically, the shares have surrendered the 50-day moving average at approximately $9.65 and are pressing toward the $7 area, with the 200-day average near $6.83 as the next meaningful reference. The 52-week range runs from $2.24 to $12.55.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Absci earns 29 out of 100.

The verified news was modest in scale: a $1 reduction to a single analyst's target, with the rating unchanged, on top of a revenue miss that was already three sessions old. Judged against a roughly $1.26 billion valuation, that is not a material fundamental shift. The price move was more notable, running about 2.6 times the stock's typical daily swing of roughly 5.2% over the past 60-odd sessions, though moves of this magnitude or larger have occurred twice in that window. Moderate news plus a somewhat unusual move combines to a low-to-mid score.

What Comes Next for ABSI

All eyes are on the December interim dataset. Investors will want to see a directionally positive hair-growth signal at 13 weeks, with the vellus-inclusive total hair count watched as a potential leading indicator, and pooled safety data free of surprises. A weak or ambiguous signal would likely force another leg of valuation compression given the binary nature of the story; a clean signal could reset expectations toward the 26-week readout in early 2027.

Analyst coverage remains constructive in aggregate — 11 of 12 rated firms sit at Buy or Strong Buy, with a mean target near $13.70 — but targets have been drifting lower. The next quarterly report is expected in the first quarter of 2027, and rising R&D expense tied to the endometriosis program and commercial build-out will be scrutinized. Key risks include clinical failure, further model-driven target cuts, dilution given a share count that has grown nearly 24% year over year, and the tendency of pre-catalyst rallies in micro-cap biotech to unwind quickly.

Trending AI Robots

Tickeron's Trending AI Robots page curates the automated trading strategies delivering the strongest results under present market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the top performers are surfaced in this section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured lineup shifts as market conditions evolve. Reviewing it regularly can help you spot approaches aligned with the current environment — explore the page to see which bots are leading today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ABSI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ABSI in downward trend: 10-day moving average moved below 50-day moving average on November 16, 2026

The 10-day moving average for ABSI crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABSI as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for ABSI turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

ABSI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 241 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

ABSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 142 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.091) is normal, around the industry mean (3.592). P/E Ratio (-12.873) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
18105 SE Mill Plain Boulevard
Phone
+1 360 949-1041
Employees
140
Web
https://www.absci.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.